Antibodies are now a mainstay cancer treatment, specifically targeting tumour (e.g. anti‐EGFR and HER2) or immune cells (e.g. anti‐CTLA4, PD‐1 and PD‐L1) (Bhandaru & Rotte, 2019). Here, ERBB2 is linked to neoplasm.